Scientific Institute of Public Health, Biosafety and Biotechnology Unit, B-1050 Brussels, Belgium.
Vaccine. 2012 Mar 30;30(16):2623-32. doi: 10.1016/j.vaccine.2012.02.016. Epub 2012 Feb 17.
The modified vaccinia virus Ankara (MVA) strain is a highly attenuated strain of vaccinia virus that has been demonstrated to be safe for humans. MVA is widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile. It also represents an excellent candidate for use as vector system in recombinant vaccine development for gene delivery or vaccination against infectious diseases or tumours, even in immunocompromised individuals. The use of MVA and recombinant MVA vectors must comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The purpose of the present paper is to highlight some biological characteristics of MVA and MVA-based recombinant vectors and to discuss these from a biosafety point of view in the context of the European regulatory framework for genetically modified organisms with emphasis on the assessment of potential risks associated with environmental release.
改良安卡拉牛痘病毒（MVA）株是一种高度减毒的牛痘病毒株，已被证明对人类是安全的。MVA 被广泛认为是临床研究中首选的牛痘病毒株，因为它具有很高的安全性。它也代表了作为基因传递或针对传染病或肿瘤进行免疫接种的重组疫苗开发的载体系统的优秀候选者，即使在免疫功能低下的个体中也是如此。MVA 和重组 MVA 载体的使用必须符合各种监管要求，特别是与对人类健康和环境的潜在风险评估有关。本文的目的是强调 MVA 和基于 MVA 的重组载体的一些生物学特性，并从生物安全的角度讨论这些特性，同时结合欧洲转基因生物监管框架，重点是评估与环境释放相关的潜在风险。
